Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX

US9422251B2 · kind B2 · utility

Assignee

• Molecular Insight Pharmaceuticals, Inc. · US

Inventors

• John W. Babich · Cambridge, US
• Craig Zimmerman · Topsfield, US
• John Joyal · Melrose, US
• Genliang Lu · Winchester, US
• Shawn Hillier · Danvers, US
• Kevin P. Maresca · Tewksbury, US
• John Marquis · Nashua, US

Key dates

• Filing date: Aug 7, 2015
• Grant date: Aug 23, 2016
• Expiry date: Aug 7, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D233/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A ligand, a pharmaceutically acceptable salt, tautomer, or ester thereof, may be represented as:In the formula, X is selected from the group consisting of —(CH2)n—, —(CH2)n—O—, —(CH2)n—N(Rg)—, —(CH2)n—N(Rg)—C(O)— and —O—; Rg is hydrogen or (C1-C6)alkyl; G is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; G′ is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; Rh is —H, —OH, NRaRb, or —CO2H; Rm is —H, —COOH, or substituted or unsubstituted —COO(C1-C6)alkyl; Ra and Rb are each independently H, substituted or unsubstituted (C1-C8)alkyl, or substituted or unsubstituted carboxy(C1-C8)alkylene; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.